CureVac NV
CVAC
Company Profile
Business description
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company’s other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.
Contact
Friedrich-Miescher-Strasse 15
TubingenBW72076
DEUT: +49 707198830
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
1,088
Stocks News & Analysis
stocks
Ask the analyst: How reliant are Guzman shares on international growth?
A year on from Guzman’s IPO, I catch up with Johannes Faul to explore what is baked into GYG’s valuation.
stocks
Nvidia: Back in business in China; Raising fair value estimate
Nvidia is poised to become more dominant than ever as it is allowed to sell its key H20 GPUs in China.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,883.10 | 66.70 | 0.76% |
| CAC 40 | 7,722.09 | 44.12 | -0.57% |
| DAX 40 | 24,009.38 | 50.91 | -0.21% |
| Dow JONES (US) | 44,254.78 | 231.49 | 0.53% |
| FTSE 100 | 8,926.55 | 11.77 | -0.13% |
| HKSE | 24,567.75 | 49.99 | 0.20% |
| NASDAQ | 20,730.49 | 52.69 | 0.25% |
| Nikkei 225 | 39,797.40 | 134.00 | 0.34% |
| NZX 50 Index | 12,905.41 | 150.82 | 1.18% |
| S&P 500 | 6,263.70 | 19.94 | 0.32% |
| S&P/ASX 200 | 8,631.70 | 69.90 | 0.82% |
| SSE Composite Index | 3,510.30 | 6.53 | 0.19% |